Urol. praxi. 2024;25(1):16-21 | DOI: 10.36290/uro.2024.012

Comination pharmacotherapy of lower urinary tract symptoms

MUDr. Marcela Fontana, Ph.D., FEBU
Urocentrum Praha
Urologická klinika 2. LF UK a FN Motol, Praha

Pharmacotherapy represents an effective treatment for most patients with lower urinary tract symptoms (LUTS). However, initial monotherapy may not lead to sufficient impact on LUTS and thus improvement in quality of life. We have medications from different drug groups, which can be effectively combined to achieve the best possible treatment effect. This text offers an overview of current pharmacotherapy of LUTS with focus on combination therapy.

Keywords: lower urinary tract symtoms, LUTS, pharmacotherapy, combination treatment.

Accepted: February 28, 2024; Published: March 15, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fontana M. Comination pharmacotherapy of lower urinary tract symptoms. Urol. praxi. 2024;25(1):16-21. doi: 10.36290/uro.2024.012.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cornu J-NL, Gravas S, Hashim H, et al. Management of Non-neurogenic Male LUTS. EAU Guidelines. Arnhem: EAU Guidelines Office; 2023. Available from: https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts.
    2. SPC jednotlivých léků, dostupné z Databáze léků. Státní ústav pro kontrolu léčiv [Internet], SÚKL: ©2010 [cit. 12.12.2023]. Available from: https://www.sukl.cz/.
    3. Barendrecht MM, Abrams P, Schumacher H, et al. Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? Neurourol Urodyn. 2008;27(3):226-230. Go to original source... Go to PubMed...
    4. Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123-131. Go to original source... Go to PubMed...
    5. Roehrborn CG, Lukkarinen O, Mark S, et al. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies. BJU Int. 2005;96(4):572-577. Go to original source... Go to PubMed...
    6. McConnell JD, Roehrborn CG, Bautista OM, et al. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387-2398. Go to original source... Go to PubMed...
    7. Roehrborn CG, Oyarzabal Perez I, Roos EP, et al. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®)) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. BJU Int. 2015;116(3):450-459. Go to original source... Go to PubMed...
    8. Gacci M, Ficarra V, Sebastianelli A, et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med. 2014;11(6):1554-1566. Go to original source... Go to PubMed...
    9. Barkin J, Guimarães M, Jacobi G, et al. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol. 2003;44(4):461-466. Go to original source... Go to PubMed...
    10. Nickel JC, Barkin J, Koch C, et al. Finasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic hyperplasia following cessation of alpha blockers. Can Urol Assoc J. 2008;2(1):16-21. Go to original source... Go to PubMed...
    11. Matoušková M, Hanuš T. Kombinovaná léčba u symptomů dolních močových cest a benigní hyperplazie prostaty. Urol. praxi. 2011;12(1):7-11.
    12. Gacci M, Sebastianelli A, Salvi M, et al. Tolterodine in the Treatment of Male LUTS. Curr Urol Rep. 2015;16(9):60. Go to original source... Go to PubMed...
    13. van Kerrebroeck P, Chapple C, Drogendijk T, et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol. 2013;64(6):1003-1012. Go to original source... Go to PubMed...
    14. Drake MJ, Oelke M, Snijder R, et al. Incidence of urinary retention during treatment with single tablet combinations of solifenacin+tamsulosin OCAS™ for up to 1 year in adult men with both storage and voiding LUTS: A subanalysis of the NEPTUNE/NEPTUNE II randomized controlled studies. PLoS One. 2017;12(2):e0170726. Go to original source... Go to PubMed...
    15. Kim HJ, Sun HY, Choi H, et al. Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis. PLoS One. 2017;12(1):e0169248. Go to original source... Go to PubMed...
    16. Kakizaki H, Lee KS, Yamamoto O, et al. Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH). Eur Urol Focus. 2020;6(4):729-737. Go to original source... Go to PubMed...
    17. Kaplan SA, Herschorn S, McVary KT, et al. Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS). J Urol. 2020;203(6):1163-1171. Go to original source... Go to PubMed...
    18. Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World J Urol. 2017;35(5):827-838. Go to original source... Go to PubMed...
    19. Soliman MG, El-Abd SA, Tawfik AM, et al. Efficacy and safety of mirabegron versus solifenacin as additional therapy for persistent OAB symptoms after tamsulosin monotherapy in men with probable BPO. World J Urol. 2021;39(6):2049-2054. Go to original source... Go to PubMed...
    20. Nagasubramanian S, John NT, Antonisamy B, et al. Tamsulosin and placebo vs tamsulosin and tadalafil in male lower urinary tract symptoms: a double-blinded, randomised controlled trial. BJU Int. 2020;125(5):718-724. Go to original source... Go to PubMed...
    21. Porst H, Oelke M, Goldfischer ER, et al. Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies. Urology. 2013;82(3):667-673. Go to original source... Go to PubMed...
    22. Donatucci CF, Brock GB, Goldfischer ER, et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. BJU Int. 2011;107(7):1110-1116. Go to original source... Go to PubMed...
    23. Gacci M, Corona G, Salvi M, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012;61(5):994-1003. Go to original source... Go to PubMed...
    24. Casabé A, Roehrborn CG, Da Pozzo LF, et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol. 2014;191(3):727-733. Go to original source... Go to PubMed...
    25. van Kerrebroeck P, Rezapour M, Cortesse A, et al. Desmopressin in the treatment of nocturia: a double-blind, placebo-controlled study. Eur Urol. 2007;52(1):221-229. Go to original source... Go to PubMed...
    26. Drlík P. Nykturie - současné možnosti terapie. Urol. praxi. 2010;11(4):176-179.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.